Bright pharmaceuticals SE: Accounting for a business combination under IFRS 3

Dominic Detzen*, Sebastian Hoffmann, Henning Zülch

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


This instructional resource familiarizes students with the accounting for business combinations under IFRS 3 and illustrates the uncertainty and professional judgment involved in asset valuation and consolidation. First, students need to assess the quality of information generated under IFRS 3 and fair value accounting. Second, they are asked to account for a business combination by identifying possible input parameters to measure several intangible assets and a contingent liability. Based on their valuation results, they compute the amount of goodwill recognized on the acquisition and assess the effects of their parameter choices on the values of different assets and liabilities. As an optional third task, the case asks students to consolidate the financial statements and evaluate the impact of the acquisition on the financial position of the acquirer.

Original languageEnglish
Pages (from-to)282-294
Number of pages13
JournalAccounting Education
Issue number3
Publication statusPublished - Jun 2013


  • Business combinations
  • goodwill
  • IFRS
  • intangible assets


Dive into the research topics of 'Bright pharmaceuticals SE: Accounting for a business combination under IFRS 3'. Together they form a unique fingerprint.

Cite this